Biomea Fusion, Inc. (BMEA) は上場企業です ヘルスケア セクターの バイオテクノロジー 業界で事業展開. 本社所在地は Redwood City, CA, アメリカ. 現CEOは Michael J. Hitchcock.
BMEA を有する IPO日 2021-04-16, 79 名の正社員, に上場 NASDAQ Global Select, 時価総額 $116.02M.
Biomea Fusion, Inc., a biopharmaceutical company, focuses on the discovery and development of covalent small molecule drugs to treat patients with genetically defined cancers and metabolic diseases. Its lead product candidate is BMF-219, an orally bioavailable, potent, and selective covalent inhibitor of menin, a transcriptional regulator in oncogenic signaling in multiple cancers. The company was incorporated in 2017 and is headquartered in Redwood City, California.
